ERBB2 and esophageal cancer: These included KGDs associated with ERBB2 amplification in breast and esophageal cancer models (e.g., ERBB2 p = 7.9 × 10−5 [breast] and p = 9.2 × 10−3 [esophageal] and MAP2K3 p = 3.3 × 10−2 [breast] and p = 4.4 × 10−3 [esophageal]; Figure S4A), but also a dependency upon the microtubule associated serine/threonine kinase MAST1 in CCND1 amplified breast or esophageal cancer models (p = 1.1 × 10−2 [breast] and p = 1.3 × 10−2 [esophageal]; Figure S3B).